The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Volkmar Mueller
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Lilly; MSD Oncology; Nektar; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Tesaro; Teva
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Hexal; Lilly; Nektar; Roche; Seagen
Research Funding - Novartis; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo; P-Value Communications; Roche
 
Virginia F. Borges
Consulting or Advisory Role - Seagen
Research Funding - AstraZeneca (Inst); Olema Oncology (Inst); oncosec (Inst); Seagen (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
Rashmi Krishna Murthy
Honoraria - AstraZeneca; Genentech; Novartis; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen
 
Alicia Frances Clare Okines
Stock and Other Ownership Interests - AstraZeneca (I)
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - Seagen
Research Funding - Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; LEO Pharma
 
Elisavet Paplomata
Honoraria - Mylan; Novartis; Pfizer; Puma Biotechnology; R-pharm
Consulting or Advisory Role - Mylan; Novartis; Pfizer; Puma Biotechnology; R-Pharm
Speakers' Bureau - OncLive Clinical Congress Consultants
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Corcept Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Immunogen (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech; Merck; Novartis; Tesaro
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis
 
Lisa A. Carey
Research Funding - Abbvie (Inst); Immunomedics (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)
 
Karen A. Gelmon
Honoraria - AstraZeneca; Merck Sharp & Dohme; Novartis Canada Pharmaceuticals Inc; Seagen
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Genomic Health; Janssen Oncology; Lilly; Merck; Mylan; NanoString Technologies; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Genentech
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Leadership - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I); Freeline Therapeutics (I); vertex (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Ionis Pharmaceuticals; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Samsung (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)
 
Mark D. Pegram
Honoraria - Genentech/Roche; Pfizer; Seagen
Consulting or Advisory Role - Genentech/Roche; Pfizer; Seagen
 
Dennis J. Slamon
Leadership - Biomarin
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer
 
Jorge Ramos
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Chiyu Zhang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Travel, Accommodations, Expenses - Seagen
 
Eric P. Winer
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Athenex; Carrick Therapeutics; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen; Syros Pharmaceuticals; Zymeworks
Research Funding - Genentech (Inst)
Other Relationship - InfiniteMD